SEC Form 4 · accession 0001562180-16-001294
Eledon Pharmaceuticals, Inc. · ELDN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jodie Pope Morrison
Officer — President and CEO · Director
Period of report
Jan 8, 2016
Accepted (ET)
Jan 8, 2016 · 4:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001404281
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 8, 2016 | M | 8,015 | $0.63 | A | 37,566 | D | |
| Common Stock | Jan 8, 2016 | M | 20,000 | $1.37 | A | 57,566 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.63 | Jan 8, 2016 | M | 8,015 | D | — | May 5, 2019 | Common Stock | 8,015 | 0 | D |
| Stock Option (right to buy)F1 | $1.37 | Jan 8, 2016 | M | 20,000 | D | — | Jun 29, 2021 | Common Stock | 20,000 | 37,878 | D |
Explanation of responses
- F1This option is fully vested.